Information Provided By:
Fly News Breaks for February 14, 2020
Feb 14, 2020 | 06:25 EDT
Citi analyst Joel Beatty downgraded Esperion Therapeutics to Neutral from Buy with a price target of $82, up from $73. Approval around the February 21 FDA action date is now largely priced into the stock, Beatty tells investors in a research note. Further, the analyst believes a moderate acquisition premium has entered the stock in recent weeks. Because of this, any gains in the stock upon approval of bempedoic acid will likely be lost over the following weeks, as it becomes apparent that Esperion will be launching the drug on their own, contends Beatty.
News For ESPR From the Last 2 Days
Dec 2, 2021 | 18:35 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGSMarvell... To see the rest of the story go to See Story Here